IP Library › Granted Patent US 11,001,638
Granted Patent B2
US 11,001,638 · App. 15/773,821 · Granted May 11, 2021

Immunomodulatory antibodies

Inventors: Aymen Al-Shamkhani (Southampton, GB); Hak Tak Claude Chan (Southampton, GB); Mark Steven Cragg (Southampton, GB); Ruth Rosemary French (Southampton, GB); Martin John Glennie (Southampton, GB); Jane Elizabeth Willoughby (Southampton, GB)
Assignee: Cancer Research Technology Limited
C07K16/2878A61K39/0011A61K39/3955A61K39/39558A61K45/06A61P35/02C07K16/2818A61K2039/505A61K2039/507A61K2039/545A61K2039/57A61K2039/575A61K2039/80C07K2317/24C07K2317/52C07K2317/53C07K2317/565C07K2317/567C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,001,638
App. No.
15/773,821
Granted
May 11, 2021
Kind
B2
Abstract

The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.

Claims (8)

1. An isolated monoclonal antibody which specifically binds to the cysteine rich repeat sequences in one or more of the extracellular domains 3 or 4 of OX40 comprising a:

(a) heavy chain CDRs comprising SEQ ID NO: 37-39 and light chain CDRs comprising SEQ ID NO: 40-42;

(b) heavy chain CDRs comprising SEQ ID NO: 43-45 and light chain CDRs comprising SEQ ID NO: 46-48;

(c) heavy chain CDRs comprising SEQ ID NO: 49-51 and light chain CDRs comprising SEQ ID NO: 52-54; or

(d) heavy chain CDRs comprising SEQ ID NO: 55-56 and light chain CDRs comprising SEQ ID NO: 58-60.

2. The isolated monoclonal antibody according to claim 1 wherein the Fc region of the antibody is derived from either the mouse IgG1 or human IgG2 isotype.

3. The isolated monoclonal antibody according to claim 2 , wherein the antibody is of hIgG2 isotype.

4. The isolated monoclonal antibody according to claim 1 comprising heavy chain CDRs having SEQ ID NO: 37-39 and light chain CDRs having SEQ ID NO: 40-42.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2018
From: AL-SHAMKHANI, AYMEN; CHAN, HAK TAK CLAUDE; CRAGG, MARK STEVEN; FRENCH, RUTH ROSEMARY; GLENNIE, MARTIN JOHN; WILLOUGHBY, JANE ELIZABETH
To: CANCER RESEARCH TECHNOLOGY LIMITED
Reel/Frame 046810/0691 →
Priority Claims (1)
GB 1519481 · Nov 4, 2015 · national
Continuity (2)
Related Publication 20180327504A1 · Nov 15, 2018
Related Publication 20200017594A9 · Jan 16, 2020